Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645749 | 0.84 | GLA (0.54) | POLBTSHRGLALMNAALDH1A1 | |
| SCHEMBL2681365 | 0.82 | ATM (0.56) | LMNAALDH1A1L3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL4326749 | 0.82 | ATM (0.50) | LMNAALDH1A1L3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL2836486 | 0.81 | ATM (0.54) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13853557 | 0.81 | GLA (0.51) | POLBTSHRGLALMNAALDH1A1 | |
| SCHEMBL7442198 | 0.80 | TAAR1 (0.51) | POLBTSHRGLALMNAALDH1A1 | |
| SCHEMBL16252568 | 0.80 | TSHR (0.50) | POLBTSHRGLALMNAALDH1A1 | |
| SCHEMBL17028378 | 0.79 | HTT (0.62) | TSHRLMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7385455 | 0.79 | GLA (0.57) | POLBTSHRGLALMNAALDH1A1 | |
| SCHEMBL23142621 | 0.78 | KDM4E (0.46) | LMNAALDH1A1L3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076279-A1 | NOVEL BENZOAZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | XUZHOU MEDICAL UNIVERSITY (CN) | 2024-03-07 | — | — | US | disclosed |
| CN-107674073-B | 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases | 印蔻真治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| EP-2571878-B1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INCOZEN THERAPEUTICS PVT LTD (IN) | 2018-10-17 | — | — | EP | disclosed |
| EP-2571878-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Incozen Therapeutics Pvt. Ltd. (IN) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076279-A1 | NOVEL BENZOAZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | AVPR1B, AVPR2, AVPR1A | POLB 4142/4885TSHR 715/4885GLA 3407/4885 |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | POLB 2836/4885TSHR 2504/4885GLA 4727/4885 |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | POLB 2836/4885TSHR 2504/4885GLA 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.